Clinical Trial Update: Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee. [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing analgesic efficacy and safety of subcutaneous tanezumab in osteoarthritis of the hip or knee has completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis of the Hip
• Osteoarthritis of the Knee

Drugs mentioned

• Tanezumab (tanezumab)

Snippet

Sponsor: Pfizer | Conditions: Osteoarthritis, Hip, Osteoarthritis, Knee | Phase 3 | Status: COMPLETED | Results posted: 2019-06-26